Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

The Lancet Oncology

Volumn 17, Issue 12, 2016, Pages 1672-1682

  Gomez, Daniel R ^a   Blumenschein, George R ^a   Lee, J Jack ^a   Hernandez, Mike ^a   Ye, Rong ^a   Camidge, D Ross ^b   Doebele, Robert C ^b   Skoulidis, Ferdinandos ^a   Gaspar, Laurie E ^b   Gibbons, Don L ^a   Karam, Jose A ^a   Kavanagh, Brian D ^b   Tang, Chad ^a   Komaki, Ritsuko ^a   Louie, Alexander V ^c   Palma, David A ^c   Tsao, Anne S ^a   Sepesi, Boris ^a   William, William N ^a   Zhang, Jianjun ^a   Shi, Qiuling ^a   Wang, Xin Shelley ^a   Swisher, Stephen G ^a   Heymach, John V ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PEMETREXED; PLATINUM COMPLEX;

ADULT; AGED; ALK GENE; ANEMIA; ARTICLE; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; EGFR GENE; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTERMETHOD COMPARISON; LEG EDEMA; LUNG RESECTION; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OBSERVATION; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 85002622789     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30532-0     Document Type: Article

References (29)

1. 1 Rusthoven, KE, Hammerman, SF, Kavanagh, BD, Birtwhistle, MJ, Stares, M, Camidge, DR, Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 48 (2009), 578–583.
2. 2 Wong, AC, Watson, SP, Pitroda, SP, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer, 2016, 10.1002/cncr.30058 published online May 20.
3. 3 Lussier, YA, Xing, HR, Salama, JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One, 6, 2011, e28650.
4. 4 Salama, JK, Chmura, SJ, Mehta, N, et al. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14 (2008), 5255–5259.
5. 5 Inoue, T, Katoh, N, Aoyama, H, et al. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. Jpn J Clin Oncol 40 (2010), 788–794.
6. 6 Pfannschmidt, J, Dienemann, H, Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer 69 (2010), 251–258.
7. 7 Khan, AJ, Mehta, PS, Zusag, TW, et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol 81 (2006), 163–167.
8. 8 Sheu, T, Heymach, JV, Swisher, SG, et al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys 90 (2014), 850–857.
9. 9 Pocock, SJ, Simon, R, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975), 103–115.
10. 10 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
11. 11 Mendoza, TR, Wang, XS, Lu, C, et al. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist 16 (2011), 217–227.
12. 12 Patel, JD, Hensing, TA, Rademaker, A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27 (2009), 3284–3289.
13. 13 Ciuleanu, T, Brodowicz, T, Zielinski, C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374 (2009), 1432–1440.
14. 14 Perol, MCB, Milleron, J, Gervais, R, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. Proc Am Soc Clin Oncol, 28(15s), 2010 Abstr 7507.
15. 15 Paz-Ares, LG, Dediu, M, Thomas, M, et al. PARAMOUNT: phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediatly following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. Proc Am Soc Clin Oncol, 29, 2011 Abstr CRA7510.
16. 16 Cappuzzo, F, Ciuleanu, T, Stelmakh, L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11 (2010), 521–529.
17. 17 Therneau, TG, Grambsch, PM, Modeling Survival Data: Extending the Cox Model, 2000, Springer, New York.
18. 18 Billing, PS, Miller, DL, Allen, MS, Deschamps, C, Trastek, VF, Pairolero, PC, Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 122 (2001), 548–553.
19. 19 Bonnette, P, Puyo, P, Gabriel, C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 119 (2001), 1469–1475.
20. 20 Hu, C, Chang, EL, Hassenbusch, SJ 3rd, et al. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106 (2006), 1998–2004.
21. 21 Iwasaki, A, Shirakusa, T, Yoshinaga, Y, Enatsu, S, Yamamoto, M, Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. Eur J Cardiothorac Surg 26 (2004), 488–493.
22. 22 Lopez Guerra, JL, Gomez, D, Zhuang, Y, et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys 84 (2012), e61–e67.
23. 23 de Vin, T, Engels, B, Gevaert, T, Storme, G, De Ridder, M, Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol 25 (2014), 467–471.
24. 24 Palma, DA, Salama, JK, Lo, SS, et al. The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 11 (2014), 549–557.
25. 25 Downey, RJ, Ng, KK, Kris, MG, et al. A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer 38 (2002), 193–197.
26. 26 De Ruysscher, D, Wanders, R, van Baardwijk, A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (NCT01282450). J Thorac Oncol 7 (2012), 1547–1555.
27. 27 Lim, SH, Lee, JY, Lee, MY, et al. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Ann Oncol 26 (2015), 762–768.
28. 28 Iyengar, P, Kavanagh, BD, Wardak, Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32 (2014), 3824–3830.
29. 29 Patel, PR, Yoo, DS, Niibe, Y, Urbanic, JJ, Salama, JK, A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. Pulm Med, 2012, 2012, 480961.